Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 107

7. BIBLIOGRAPHY

1 Kamm MA. Inflammatory Bowel Disease, 2 edn.: Taylor & Francis, 1999.

2 Kumar V et al. Robbins and Cotrans Pathologic Basis of Disease, 7 edn. New

Delhi: Reed Elsevier India Private Limited, New Delhi, 2007.

3 Lam CH. Effect of Scutellariae Radix Extract and Its Major Flavonoid,

Baicalein, on Colonic Epithelial Ion Transport and Experimental Colitis in

Rats. Hong Kong: Chinese University of Hong Kong, 2007.

4 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects

and established and evolving therapies. Lancet 2007; 9573: 1641-1657.

5 Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into

pathogenesis and treatment. J Intern Med 2002; 6: 475-496.

6 Rutgeerts P et al. Optimizing anti-TNF treatment in inflammatory bowel

disease. Gastroenterology 2004; 6: 1593-1610.

7 Martinez-Montiel MP, Munoz-Yague MT. Biologic therapies for chronic

inflammatory bowel disease. Rev Esp Enferm Dig 2006; 4: 265-291.

8 Geier MS et al. Inflammatory bowel disease: current insights into

pathogenesis and new therapeutic options; probiotics, prebiotics and

synbiotics. Int J Food Microbiol 2007; 1: 1-11.

9 Maiti R et al. Antidiabetic effect of aqueous extract of seed of Tamarindus

indica in streptozotocin-induced diabetic rats. J Ethnopharmacol 2004; 1: 85-

91.

10 Kalaivani T, Mathew L. Phytochemistry and free radical scavenging activities

of Oroxylum indicum. Environ We Int J Sci Tech 2009: 45-52.

11 Liu R et al. Preparative isolation of flavonoid compounds from Oroxylum

indicum by high-speed counter-current chromatography by using ionic liquids

as the modifier of two-phase solvent system. J Sep Sci 2010; 8: 1058-1063.

12 Jabeen N et al. Callus induction and organogenesis from explants of Aconitum

heterophyllum- medicinal plant. Biotechnology 2006; 3: 287-291.

13 Brijesh S et al. Studies on the antidiarrhoeal activity of Aegle marmelos unripe

fruit: validating its traditional usage. BMC Complement Altern Med 2009: 47.

14 Gasche C et al. A simple classification of Crohn's disease: report of the

Working Party for the World Congresses of Gastroenterology, Vienna 1998.

Inflamm Bowel Dis 2000; 1: 8-15.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 108

15 Silverberg MS et al. Toward an integrated clinical, molecular and serological

classification of inflammatory bowel disease: Report of a Working Party of

the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol

2005: 5-36.

16 Louis E et al. Behaviour of Crohn's disease according to the Vienna

classification: changing pattern over the course of the disease. Gut 2001; 6:

777-782.

17 Tandon BN et al. Ulcerative Colitis in North Indian Subjects: A Preliminary

Report. J Assoc Physicians India 1964: 43-52.

18 Pai CG, Khandige GK. Is Crohn's disease rare in India? Indian J

Gastroenterol 2000; 1: 17-20.

19 Probert CS et al. Inflammatory bowel disease in the rural Indian subcontinent:

a survey of patients attending mission hospitals. Digestion 1990; 1: 42-46.

20 Pulimood AB et al. Endoscopic mucosal biopsies are useful in distinguishing

granulomatous colitis due to Crohn's disease from tuberculosis. Gut 1999; 4:

537-541.

21 Bhansali SK. Abdominal tuberculosis. Experiences with 300 cases. Am J

Gastroenterol 1977; 4: 324-337.

22 Das P, Shukla HS. Clinical diagnosis of abdominal tuberculosis. Br J Surg

1976; 12: 941-946.

23 Kapoor VK. Abdominal tuberculosis: the Indian contribution. Indian J

Gastroenterol 1998; 4: 141-147.

24 Prakash A. Ulcero-constrictive tuberculosis of the bowel. Int Surg 1978; 5: 23-

29.

25 Bach JF. The effect of infections on susceptibility to autoimmune and allergic

diseases. N Engl J Med 2002; 12: 911-920.

26 Weiss ST. Eat dirt--the hygiene hypothesis and allergic diseases. N Engl J

Med 2002; 12: 930-931.

27 Antia PF et al. Incidence of Intestinal Helminths in Bombay. Indian J Med Sci

1964: 635-638.

28 Weinstock JV et al. Helminths and harmony. Gut 2004; 1: 7-9.

29 Allchin WH. A Discussion on "Ulcerative Colitis.": Introductory Address.

Proc R Soc Med 1909; Med Sect: 59-75.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 109

30 Crohn BB et al. Landmark article Oct 15, 1932. Regional ileitis. A

pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and

Gordon D. Oppenheimer. JAMA 1984; 1: 73-79.

31 Mayberry J, Mann R. Inflammatory bowel disease in rural sub-Saharan Africa:

rarity of diagnosis in patients attending mission hospitals. Digestion 1989; 3:

172-176.

32 Van Heel DA et al. Crohn's disease: genetic susceptibility, bacteria, and innate

immunity. Lancet 2001; 9272: 1902-1904.

33 Elson CO et al. Experimental models of inflammatory bowel disease reveal

innate, adaptive, and regulatory mechanisms of host dialogue with the

microbiota. Immunol Rev 2005: 260-276.

34 Shanahan F. Crohn's disease. Lancet 2002; 9300: 62-69.

35 Satsangi J et al. Contribution of genes of the major histocompatibility complex

to susceptibility and disease phenotype in inflammatory bowel disease. Lancet

1996; 9010: 1212-1217.

36 Duchmann R et al. Tolerance exists towards resident intestinal flora but is

broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;

3: 448-455.

37 Woodruff TM et al. Increased potency of a novel complement factor 5a

receptor antagonist in a rat model of inflammatory bowel disease. J

Pharmacol Exp Ther 2005; 2: 811-817.

38 Dieckgraefe BK et al. Growth factors as treatment options for intestinal

inflammation. Ann N Y Acad Sci 2006: 300-306.

39 Kelsall BL, Leon F. Involvement of intestinal dendritic cells in oral tolerance,

immunity to pathogens, and inflammatory bowel disease. Immunol Rev 2005:

132-148.

40 Twig G et al. Systemic thromboembolism in inflammatory bowel disease:

mechanisms and clinical applications. Ann N Y Acad Sci 2005: 166-173.

41 Mccartney SA et al. Selective COX-2 inhibitors and human inflammatory

bowel disease. Aliment Pharmacol Ther 1999; 8: 1115-1117.

42 Di Sabatino A et al. Targeting gut T cell Ca2+ release-activated Ca2+

channels inhibits T cell cytokine production and T-box transcription factor T-

bet in inflammatory bowel disease. J Immunol 2009; 5: 3454-3462.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 110

43 Parekh AB. Store-operated CRAC channels: function in health and disease.

Nat Rev Drug Discov 2010; 5: 399-410.

44 Parekh AB, Putney JW, Jr. Store-operated calcium channels. Physiol Rev

2005; 2: 757-810.

45 Boer K et al. Decreased expression of histamine H1 and H4 receptors suggests

disturbance of local regulation in human colorectal tumours by histamine. Eur

J Cell Biol 2008; 4: 227-236.

46 Matsubara M et al. Histamine H1 receptor antagonist blocks histamine-

induced proinflammatory cytokine production through inhibition of Ca2+-

dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B

signal cascades. Biochem Pharmacol 2005; 3: 433-449.

47 Zocco D et al. Histamine modulation of peripheral CRH receptor type 1alpha

expression is dependent on Ca(2+) signalling and NF-kappaB/p65

transcriptional activity. Mol Immunol 2010; 7-8: 1426-1437.

48 Zhang M et al. The histamine H(4) receptor: a novel modulator of

inflammatory and immune disorders. Pharmacol Ther 2007; 3: 594-606.

49 Takeshita K et al. Critical role of histamine H4 receptor in leukotriene B4

production and mast cell-dependent neutrophil recruitment induced by

zymosan in vivo. J Pharmacol Exp Ther 2003; 3: 1072-1078.

50 Thurmond RL et al. A potent and selective histamine H4 receptor antagonist

with anti-inflammatory properties. J Pharmacol Exp Ther 2004; 1: 404-413.

51 Ajuebor MN et al. Role of resident peritoneal macrophages and mast cells in

chemokine production and neutrophil migration in acute inflammation:

evidence for an inhibitory loop involving endogenous IL-10. J Immunol 1999;

3: 1685-1691.

52 Kolaczkowska E et al. Role of mast cells in zymosan-induced peritoneal

inflammation in Balb/c and mast cell-deficient WBB6F1 mice. J Leukoc Biol

2001; 1: 33-42.

53 Sato M et al. Direct binding of Toll-like receptor 2 to zymosan, and zymosan-

induced NF-kappa B activation and TNF-alpha secretion are down-regulated

by lung collectin surfactant protein A. J Immunol 2003; 1: 417-425.

54 Lakatos PL et al. Current concept on the pathogenesis of inflammatory bowel

disease-crosstalk between genetic and microbial factors: pathogenic bacteria

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 111

and altered bacterial sensing or changes in mucosal integrity take "toll" ?

World J Gastroenterol 2006; 12: 1829-1841.

55 Canto E et al. TNF alpha production to TLR2 ligands in active IBD patients.

Clin Immunol 2006; 2: 156-165.

56 Sander LE et al. Selective expression of histamine receptors H1R, H2R, and

H4R, but not H3R, in the human intestinal tract. Gut 2006; 4: 498-504.

57 Breunig E et al. Histamine excites neurones in the human submucous plexus

through activation of H1, H2, H3 and H4 receptors. J Physiol 2007; Pt 2: 731-

742.

58 Varga C et al. Inhibitory effects of histamine H4 receptor antagonists on

experimental colitis in the rat. Eur J Pharmacol 2005; 1-3: 130-138.

59 Weir HK et al. Annual report to the nation on the status of cancer, 1975-2000,

featuring the uses of surveillance data for cancer prevention and control. J

Natl Cancer Inst 2003; 17: 1276-1299.

60 Langholz E et al. Colorectal cancer risk and mortality in patients with

ulcerative colitis. Gastroenterology 1992; 5: 1444-1451.

61 Eaden JA et al. The risk of colorectal cancer in ulcerative colitis: a meta-

analysis. Gut 2001; 4: 526-535.

62 Meira LB et al. DNA damage induced by chronic inflammation contributes to

colon carcinogenesis in mice. J Clin Invest 2008; 7: 2516-2525.

63 Hussain SP et al. Radical causes of cancer. Nat Rev Cancer 2003; 4: 276-285.

64 Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to

cancer development and progression. Nat Rev Immunol 2005; 10: 749-759.

65 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 6917: 860-

867.

66 Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol

2002; 3: 221-227.

67 Greten FR et al. IKKbeta links inflammation and tumorigenesis in a mouse

model of colitis-associated cancer. Cell 2004; 3: 285-296.

68 Herfarth H et al. Nuclear factor-kappa B activity and intestinal inflammation

in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by

gliotoxin. Clin Exp Immunol 2000; 1: 59-65.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 112

69 Wullaert A et al. NF-kappaB in the regulation of epithelial homeostasis and

inflammation. Cell Res 2011; 1: 146-158.

70 Egan LJ et al. IkappaB-kinasebeta-dependent NF-kappaB activation provides

radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A 2004; 8:

2452-2457.

71 Westbrook AM et al. Mechanisms of intestinal inflammation and development

of associated cancers: lessons learned from mouse models. Mutat Res 2010; 1:

40-59.

72 Scheller J et al. The pro- and anti-inflammatory properties of the cytokine

interleukin-6. Biochim Biophys Acta 2011; 5: 878-888.

73 Grivennikov S et al. IL-6 and Stat3 are required for survival of intestinal

epithelial cells and development of colitis-associated cancer. Cancer Cell

2009; 2: 103-113.

74 Mullberg J et al. The soluble interleukin-6 receptor is generated by shedding.

Eur J Immunol 1993; 2: 473-480.

75 Hurst SM et al. Il-6 and its soluble receptor orchestrate a temporal switch in

the pattern of leukocyte recruitment seen during acute inflammation. Immunity

2001; 6: 705-714.

76 Jones SA. Directing transition from innate to acquired immunity: defining a

role for IL-6. J Immunol 2005; 6: 3463-3468.

77 Kaplanski G et al. IL-6: a regulator of the transition from neutrophil to

monocyte recruitment during inflammation. Trends Immunol 2003; 1: 25-29.

78 Romano M et al. Role of IL-6 and its soluble receptor in induction of

chemokines and leukocyte recruitment. Immunity 1997; 3: 315-325.

79 Chen Q et al. Central role of IL-6 receptor signal-transducing chain gp130 in

activation of L-selectin adhesion by fever-range thermal stress. Immunity

2004; 1: 59-70.

80 Langmead L, Rampton DS. Review article: complementary and alternative

therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006; 3:

341-349.

81 Langmead L et al. Antioxidant effects of herbal therapies used by patients

with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther

2002; 2: 197-205.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 113

82 Langmead L et al. Randomized, double-blind, placebo-controlled trial of oral

aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004; 7:

739-747.

83 Gupta I et al. Effects of Boswellia serrata gum resin in patients with ulcerative

colitis. Eur J Med Res 1997; 1: 37-43.

84 Hausmann M et al. In vivo treatment with the herbal phenylethanoid acteoside

ameliorates intestinal inflammation in dextran sulphate sodium-induced

colitis. Clin Exp Immunol 2007; 2: 373-381.

85 Nakhai LA et al. Benefits of Zataria multiflora Boiss in Experimental Model

of Mouse Inflammatory Bowel Disease. Evid Based Complement Alternat

Med 2007; 1: 43-50.

86 Ghafari H et al. Protection by Ziziphora clinopoides of acetic acid-induced

toxic bowel inflammation through reduction of cellular lipid peroxidation and

myeloperoxidase activity. Hum Exp Toxicol 2006; 6: 325-332.

87 Kil JS et al. Inhibitory effects of Angelicae Gigantis Radix on osteoclast

formation. Phytother Res 2008; 4: 472-476.

88 Leung TF et al. In vitro and clinical immunomodulatory effects of a novel

Pentaherbs concoction for atopic dermatitis. Br J Dermatol 2008; 6: 1216-

1223.

89 Jin UH et al. Inhibition of mouse osteoblast proliferation and prostaglandin E2

synthesis by Ulmus davidiana Planch (Ulmaceae). Food Chem Toxicol 2008;

6: 2135-2142.

90 Shichijo K, Saito H. Effect of Chinese herbal medicines and disodium

cromoglycate on IgE-dependent histamine release from mouse cultured mast

cells. Int J Immunopharmacol 1997; 11-12: 677-682.

91 Dietert RR, Dietert JM. Early-life immune insult and developmental

immunotoxicity (DIT)-associated diseases: potential of herbal- and fungal-

derived medicinals. Curr Med Chem 2007; 10: 1075-1085.

92 Ko E et al. Sophorae radix reduces autoimmune response in NZB/w F1

systemic lupus erythematosus mouse model. Lupus 2007; 5: 335-341.

93 Lee LS et al. Possible differential induction of phase 2 enzyme and antioxidant

pathways by american ginseng, Panax quinquefolius. J Clin Pharmacol 2008;

5: 599-609.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 114

94 Nadkarni KM. Dr. KM Nadkarni's Indian Materia Medica, 2: Popular

Prakashan, 1996.

95 Hong T et al. Evaluation of the anti-inflammatory effect of baicalein on

dextran sulfate sodium-induced colitis in mice. Planta Med 2002; 3: 268-271.

96 Khennouf S et al. Effect of tannins from Quercus suber and Quercus coccifera

leaves on ethanol-induced gastric lesions in mice. J Agric Food Chem 2003; 5:

1469-1473.

97 Ng TB et al. Antioxidative activity of natural products from plants. Life Sci

2000; 8: 709-723.

98 Chiang LC et al. Immunomodulatory activities of flavonoids, monoterpenoids,

triterpenoids, iridoid glycosides and phenolic compounds of Plantago species.

Planta Med 2003; 7: 600-604.

99 Kujumgiev A et al. Antibacterial, antifungal and antiviral activity of propolis

of different geographic origin. J Ethnopharmacol 1999; 3: 235-240.

100 Knight DC, Eden JA. A review of the clinical effects of phytoestrogens.

Obstet Gynecol 1996; 5 Pt 2: 897-904.

101 Ravi S et al. In vitro glucose uptake by isolated rat hemi-diaphragm study of

Aegle marmelos Correa root. Bangladesh Journal of Pharmacology 2008; 1:

65-68.

102 Khandelwal KR. Practical Pharmacognosy, Pune Nirali Prakashan

Publishers, 2006.

103 Meyer SA et al. Up‐and‐down procedure (UDP) determinations of acute oral

toxicity of nitroso degradation products of hexahydro‐1, 3, 5‐trinitro‐1, 3,

5‐triazine (RDX). Journal of applied toxicology 2005; 5: 427-434.

104 Thatte UM et al. The flip side of Ayurveda. J Postgrad Med 1993; 4: 179-182,

182a-182b.

105 Veerappan A et al. Acute and subacute toxicity studies of Aegle marmelos

Corr., an Indian medicinal plant. Phytomedicine 2007; 2-3: 209-215.

106 Ferrero A et al. Acute and subacute toxicity evaluation of ethanolic extract

from fruits of Schinus molle in rats. J Ethnopharmacol 2007; 3: 441-447.

107 Mukinda JT, Syce JA. Acute and chronic toxicity of the aqueous extract of

Artemisia afra in rodents. J Ethnopharmacol 2007; 1: 138-144.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 115

108 Baird SJ et al. Evaluation of effect profiles: Functional Observational Battery

outcomes. Fundam Appl Toxicol 1997; 1: 37-51.

109 Gandhi T et al. Effect of Aegle marmelos Linn.(Rutaceae) fruits in

inflammatory bowel disease. 2009.

110 Cuzzocrea S et al. Calpain inhibitor I reduces colon injury caused by

dinitrobenzene sulphonic acid in the rat. Gut 2001; 4: 478-488.

111 Khan HA. Computer-assisted visualization and quantitation of experimental

gastric lesions in rats. J Pharmacol Toxicol Methods 2004; 2: 89-95.

112 Ko JK et al. Amelioration of experimental colitis by Astragalus

membranaceus through anti-oxidation and inhibition of adhesion molecule

synthesis. World J Gastroenterol 2005; 37: 5787-5794.

113 Mitra SKS, A.; Udupa, V. . Experimental evaluation of Diarex Vet in lactose

induced diarrhoea in rats. . Ind Vet J 2001: 212-216.

114 Teke GN et al. Antidiarrhoeal and antimicrobial activities of Emilia coccinea

(Sims) G. Don extracts. J Ethnopharmacol 2007; 2: 278-283.

115 Rouf R et al. Assessment of antidiarrhoeal activity of the methanol extract of

Xylocarpus granatum bark in mice model. J Ethnopharmacol 2007; 3: 539-

542.

116 Borrelli F et al. Effect of Boswellia serrata on intestinal motility in rodents:

inhibition of diarrhoea without constipation. Br J Pharmacol 2006; 4: 553-

560.

117 Adeyemi OO, Akindele AJ. Antidiarrhoeal activity of the ethyl acetate extract

of Baphia nitida (Papilionaceae). J Ethnopharmacol 2008; 3: 407-412.

118 Tanaka T et al. Melatonin suppresses AOM/DSS-induced large bowel

oncogenesis in rats. Chem Biol Interact 2009; 2: 128-136.

119 Suleiman MM et al. Antidiarrhoeal activity of the methanol stem-bark extract

of Annona senegalensis Pers. (Annonaceae). J Ethnopharmacol 2008; 1: 125-

130.

120 Ohta T et al. Ca2+ entry activated by emptying of intracellular Ca2+ stores in

ileal smooth muscle of the rat. Br J Pharmacol 1995; 6: 1165-1170.

121 Kulkarni SK. Handbook of Experimental Pharmacology, 3 edn. Delhi:

Vallabh Prakashan, 2006.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 116

122 Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an

overview. Surg Clin North Am 2007; 3: 575-585.

123 Shaw D et al. Pharmacovigilance of herbal medicine. J Ethnopharmacol 2012;

3: 513-518.

124 Zhang J et al. Quality of herbal medicines: challenges and solutions.

Complement Ther Med 2012; 1-2: 100-106.

125 Head KA, Jurenka JS. Inflammatory bowel disease Part 1: ulcerative colitis--

pathophysiology and conventional and alternative treatment options. Altern

Med Rev 2003; 3: 247-283.

126 Lennie TA et al. Activity of body energy regulatory pathways in

inflammation-induced anorexia. Physiol Behav 2001; 4: 517-523.

127 Ashkar AA et al. Toll-like receptor (TLR)-3, but not TLR4, agonist protects

against genital herpes infection in the absence of inflammation seen with CpG

DNA. J Infect Dis 2004; 10: 1841-1849.

128 Alzoghaibi MA et al. Lipid peroxides in patients with inflammatory bowel

disease. Saudi J Gastroenterol 2007; 4: 187-190.

129 Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 6: 365-376.

130 Kooij A. A re-evaluation of the tissue distribution and physiology of xanthine

oxidoreductase. Histochem J 1994; 12: 889-915.

131 Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of

inflammatory bowel disease. Kurume Med J 1998; 1: 69-73.

132 Sedghi S et al. Increased production of luminol enhanced chemiluminescence

by the inflamed colonic mucosa in patients with ulcerative colitis. Gut 1993;

9: 1191-1197.

133 Reynolds PD et al. Xanthine oxidase activity is not increased in the colonic

mucosa of ulcerative colitis. Aliment Pharmacol Ther 1996; 5: 737-741.

134 Kruidenier L et al. Intestinal oxidative damage in inflammatory bowel disease:

semi-quantification, localization, and association with mucosal antioxidants. J

Pathol 2003; 1: 28-36.

135 Rachmilewitz D et al. Enhanced colonic nitric oxide generation and nitric

oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 1995; 5:

718-723.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 117

136 Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J

1992; 12: 3051-3064.

137 Gaginella TS et al. Reactive oxygen and nitrogen metabolites as mediators of

secretory diarrhea. Gastroenterology 1995; 6: 2019-2028.

138 Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation,

and ischemia-reperfusion injury. Shock 1996; 2: 79-88.

139 Crow JP, Beckman JS. The role of peroxynitrite in nitric oxide-mediated

toxicity. Curr Top Microbiol Immunol 1995: 57-73.

140 Phelps DT et al. TNF-alpha induces peroxynitrite-mediated depletion of lung

endothelial glutathione via protein kinase C. Am J Physiol 1995; 4 Pt 1: L551-

559.

141 Inoue S, Kawanishi S. Oxidative DNA damage induced by simultaneous

generation of nitric oxide and superoxide. FEBS Lett 1995; 1: 86-88.

142 Lebeau A et al. Baicalein protects cortical neurons from beta-amyloid (25-35)

induced toxicity. Neuroreport 2001; 10: 2199-2202.

143 Ishige K et al. Flavonoids protect neuronal cells from oxidative stress by three

distinct mechanisms. Free Radic Biol Med 2001; 4: 433-446.

144 Lee HH et al. Differential effects of natural polyphenols on neuronal survival

in primary cultured central neurons against glutamate- and glucose

deprivation-induced neuronal death. Brain Res 2003; 1-2: 103-113.

145 Suk K et al. Flavonoid baicalein attenuates activation-induced cell death of

brain microglia. J Pharmacol Exp Ther 2003; 2: 638-645.

146 Wardlaw A, Walsh G. Neutrophil adhesion receptors. In: Hellewell, P.,

Williams, T. eds. Immunopharmacology of Neutrophils. San Diego: Academic

Press, 1994: 134– 157.

147 Chen YC et al. Wogonin, baicalin, and baicalein inhibition of inducible nitric

oxide synthase and cyclooxygenase-2 gene expressions induced by nitric

oxide synthase inhibitors and lipopolysaccharide. Biochem Pharmacol 2001;

11: 1417-1427.

148 Buffinton GD, Doe WF. Depleted mucosal antioxidant defences in

inflammatory bowel disease. Free Radic Biol Med 1995; 6: 911-918.

149 Sido B et al. Impairment of intestinal glutathione synthesis in patients with

inflammatory bowel disease. Gut 1998; 4: 485-492.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 118

150 Crisafulli C et al. Effects of genetic and pharmacological inhibition of TNF-

alpha in the regulation of inflammation in macrophages. Pharmacol Res 2009;

4: 332-340.

151 Lin WW, Karin M. A cytokine-mediated link between innate immunity,

inflammation, and cancer. J Clin Invest 2007; 5: 1175-1183.

152 Ditsworth D, Zong WX. NF-kappaB: key mediator of inflammation-associated

cancer. Cancer Biol Ther 2004; 12: 1214-1216.

153 Pikarsky E et al. NF-kappaB functions as a tumour promoter in inflammation-

associated cancer. Nature 2004; 7007: 461-466.

154 Ha SK et al. Chrysin suppresses LPS-stimulated proinflammatory responses

by blocking NF-kappaB and JNK activations in microglia cells. Neurosci Lett

2010; 3: 143-147.

155 Kole L et al. Biochanin-A, an isoflavon, showed anti-proliferative and anti-

inflammatory activities through the inhibition of iNOS expression, p38-

MAPK and ATF-2 phosphorylation and blocking NFkappaB nuclear

translocation. Eur J Pharmacol 2011; 1-3: 8-15.

156 Tanaka T, Kishimoto T. Immunotherapeutic implication of IL-6 blockade.

Immunotherapy 2012; 1: 87-105.

157 Tanaka T et al. Therapeutic targeting of the interleukin-6 receptor. Annu Rev

Pharmacol Toxicol 2012: 199-219.

158 Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of

inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol

2005; 3: 187-196.

159 Heikkila K et al. Systematic review of the association between circulating

interleukin-6 (IL-6) and cancer. Eur J Cancer 2008; 7: 937-945.

160 Becker C et al. TGF-beta suppresses tumor progression in colon cancer by

inhibition of IL-6 trans-signaling. Immunity 2004; 4: 491-501.

161 Becker C et al. IL-6 signaling promotes tumor growth in colorectal cancer.

Cell Cycle 2005; 2: 217-220.

162 Hill SJ et al. International Union of Pharmacology. XIII. Classification of

histamine receptors. Pharmacol Rev 1997; 3: 253-278.

163 Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J

1998: 281-292.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 119

164 Chen CC et al. TNF-alpha-induced cyclooxygenase-2 expression in human

lung epithelial cells: involvement of the phospholipase C-gamma 2, protein

kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B

kinase 1/2 pathway. J Immunol 2000; 5: 2719-2728.

165 Guha S et al. Neurotensin stimulates protein kinase C-dependent mitogenic

signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res 2003;

10: 2379-2387.

166 Jiang F et al. Fibronectin- and protein kinase C-mediated activation of

ERK/MAPK are essential for proplateletlike formation. Blood 2002; 10: 3579-

3584.

167 Leitges M et al. Targeted disruption of the zetaPKC gene results in the

impairment of the NF-kappaB pathway. Mol Cell 2001; 4: 771-780.

168 Muscella A et al. PKC-zeta is required for angiotensin II-induced activation of

ERK and synthesis of C-FOS in MCF-7 cells. J Cell Physiol 2003; 1: 61-68.

169 Robin P et al. ET-1 stimulates ERK signaling pathway through sequential

activation of PKC and Src in rat myometrial cells. Am J Physiol Cell Physiol

2002; 1: C251-260.

170 Trushin SA et al. Protein kinase Calpha (PKCalpha) acts upstream of

PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes. Mol

Cell Biol 2003; 19: 7068-7081.

171 Vancurova I et al. NF-kappa B activation in tumor necrosis factor alpha-

stimulated neutrophils is mediated by protein kinase Cdelta. Correlation to

nuclear Ikappa Balpha. J Biol Chem 2001; 23: 19746-19752.

172 Vertegaal AC et al. Protein kinase C-alpha is an upstream activator of the

IkappaB kinase complex in the TPA signal transduction pathway to NF-

kappaB in U2OS cells. Cell Signal 2000; 11-12: 759-768.

173 Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated

by ERK, JNK, and p38 protein kinases. Science 2002; 5600: 1911-1912.

174 Schwarz A et al. Ca2+ signaling in identified T-lymphocytes from human

intestinal mucosa. Relation to hyporeactivity, proliferation, and inflammatory

bowel disease. J Biol Chem 2004; 7: 5641-5647.

175 Lewis RS. Calcium signaling mechanisms in T lymphocytes. Annu Rev

Immunol 2001: 497-521.

Bibliography

Phytopharmacological evaluation of some plants useful in treatment of Inflammatory Bowel Disease 120

176 Putney JW, Jr., Bird GS. The signal for capacitative calcium entry. Cell 1993;

2: 199-201.

177 Hoth M. Calcium and barium permeation through calcium release-activated

calcium (CRAC) channels. Pflugers Arch 1995; 3: 315-322.

178 Zweifach A, Lewis RS. Mitogen-regulated Ca2+ current of T lymphocytes is

activated by depletion of intracellular Ca2+ stores. Proc Natl Acad Sci U S A

1993; 13: 6295-6299.

179 Parekh AB, Penner R. Store depletion and calcium influx. Physiol Rev 1997;

4: 901-930.

180 Fanger CM et al. Characterization of T cell mutants with defects in

capacitative calcium entry: genetic evidence for the physiological roles of

CRAC channels. J Cell Biol 1995; 3: 655-667.

181 Partiseti M et al. The calcium current activated by T cell receptor and store

depletion in human lymphocytes is absent in a primary immunodeficiency. J

Biol Chem 1994; 51: 32327-32335.

182 Le Deist F et al. A primary T-cell immunodeficiency associated with defective

transmembrane calcium influx. Blood 1995; 4: 1053-1062.

183 Feske S et al. Gene regulation mediated by calcium signals in T lymphocytes.

Nat Immunol 2001; 4: 316-324.

184 Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev

Immunol 2007; 9: 690-702.

185 Bae Y et al. Chrysin suppresses mast cell-mediated allergic inflammation:

involvement of calcium, caspase-1 and nuclear factor-kappaB. Toxicol Appl

Pharmacol 2011; 1: 56-64.

186 Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines.

Trends Pharmacol Sci 2002; 3: 136-139.